


1647

Please Direct All Correspondence to Customer Number **30,313**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard et al.

App. No : 10/063,602

Filed : May 3, 2002

For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME

Examiner : Sandra L. Wegert


Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 25, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:


(X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:


(X) Listing 48 references.

(X) Enclosing 35 references.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.


AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Goddard et al.
App. No : 10/063,602
Filed : May 3, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Sandra L. Wegert
Art Unit : 1647

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 48 references to be considered by the Examiner. Also enclosed are 35 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 25, 2005

By: AnneMarie Kaiser
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/063,602
	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
SHEET 1 OF 3	Examiner	Sandra L. Wegert
	Attorney Docket No.	GNE.3230R1C74


U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, D.	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582 B1	05-08-2001	Rodier, et al.	
	6	6,395,306 B1	05-28-2002	Cui, et al.	
	7	6,414,117 B1	07-02-2002	Levinson, D. A.	
	8	6,465,185 B1	10-15-2002	Goldfine, et al.	
	9	6,498,235 B2	12-24-2002	Sheppard, et al.	
	10	6,562,343 B1	05-13-2003	Levinson, D. A.	
	11	6,645,499 B1	11-11-2003	Lal, et al.	
	12	6,730,502 B2	05-04-2004	Van Hijum, et al.	
	13	6,737,522 B2	05-18-2004	Sundick, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	14	WO 97/38085	10-16-1997	California Pacific Medical Center		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.		
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.		
	17	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.		
	18	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular & Cellular Proteomics</i> 1.4, pp. 304-313.		

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Application No.	10/063,602
	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 2 OF 3	Attorney Docket No.	GNE.3230R1C74

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	19	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	20	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	
	21	GÖKMEN-POLAR, et al. 2001. Elevated protein kinase C β II is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.	
	22	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	23	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	24	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	25	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	26	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	27	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	28	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	
	29	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	30	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	31	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> , 15(5):469-483. (Abstract).	
	32	KONOPKA, et al. 1986. Variable expression of the translocated <i>c-abl</i> oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	33	Laird, 2001, Accession No. AL445222	
	34	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	35	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	36	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,602
	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 3 OF 3	Attorney Docket No.	GNE.3230R1C74

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	37	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	38	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.	
	39	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	40	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	41	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411-421. (Abstract).	
	42	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (<i>HER-2/neu</i>) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
	43	Strausberg, et al., 2003, Accession No. AAH20905.1	
	44	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	
	45	VALLEJO, et al. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> , 82(12):1129-1133. (Abstract).	
	46	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	47	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	
	48	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	

1827684/jk
072205

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.